RECRUITINGEarly Phase 1INTERVENTIONAL
Entire-body PET Scans for Multiple Sclerosis
Exploratory Study of Entire-body PET Scans for Multiple Sclerosis
About This Trial
To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.
Who May Be Eligible (Plain English)
Who May Qualify:
- Multiple sclerosis (MS) patients diagnosed by a credentialed neurologist experienced with care of multiple sclerosis patients.
- Normal healthy subjects.
- Willing and able to lie motionless on the PET-CT scanner bed for at least 10 minutes and up to 20 minutes for the duration of the PET-CT medical imaging scan.
Who Should NOT Join This Trial:
- Any additional complicating medical illness other than MS including any other neuropsychiatric illness unrelated to MS diagnosed prior to the onset of initial symptoms of MS.
- Pregnancy or breast feeding.
- Diabetes or other metabolic-endocrine disorders.
- Any known concomitant acute infection.
- History of metastatic or locally invasive cancer.
- Recent surgery, chemotherapy or radiation therapy.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Multiple sclerosis (MS) patients diagnosed by a credentialed neurologist experienced with care of multiple sclerosis patients.
* Normal healthy subjects.
* Willing and able to lie motionless on the PET-CT scanner bed for at least 10 minutes and up to 20 minutes for the duration of the PET-CT medical imaging scan.
Exclusion Criteria:
* Any additional complicating medical illness other than MS including any other neuropsychiatric illness unrelated to MS diagnosed prior to the onset of initial symptoms of MS.
* Pregnancy or breast feeding.
* Diabetes or other metabolic-endocrine disorders.
* Any known concomitant acute infection.
* History of metastatic or locally invasive cancer.
* Recent surgery, chemotherapy or radiation therapy.
Treatments Being Tested
DIAGNOSTIC_TEST
Entire-body PET-CT scans
Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.
DRUG
Amyvid radiopharmaceutical
Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants
Locations (1)
Brain Health Alliance
Ladera Ranch, California, United States